Longy pushes blood + genetics
Longy Health is promoting blood and genetic analysis as a step beyond wearables for deeper health optimization and preventive care — the pitch leans on lab and genomic signals rather than activity‑only data streams. The move signals growing interest in integrating molecular profiling into personalized fitness and metabolic risk plans. (x.com)
Longy’s website brands the product as a “Central Nervous System” for longevity and explicitly says it aims to bridge clinical‑grade data with day‑to‑day recommendations. (longy.life) The company lists hardware integration with Oura, WHOOP and Apple devices and states that it ingests “clinical lab markers” alongside wearable telemetry. (longy.life) Longy says it is running an Open Testing program and an Android beta, describing its reasoning engine as “in active training” and its protocols as experimental. (longy.life) The Longy app is published on the Apple App Store under app id 6753913293. (apps.apple.com) A Google Play listing exists under package com.executeai.longylife and the Play entry shows the app is available through the developer’s beta channel. (play.google.com) The company’s services page advertises health‑monitoring packages and lists a “Basic Health Plan” price on the page, and the site markets both consumer features and enterprise offerings. (longy.life) Longy frames its business case around a projected $46 billion “longevity economy” opportunity and specifically pitches workforce hardware optimization for high‑stress sectors. (longy.life)
